mCRPC Clinical Trial
Official title:
Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically to the concurrently administered immunotherapy Sipuleucel-T and thereby significantly improve the treatment outcome for metastatic castrate resistant prostate cancer patients (mCRPC). Both Sipuleucel-T and SABR are FDA approved therapeutic cancer treatment
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05383079 -
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06056791 -
Study of INKmune in Patients With mCRPC (CaRe Prostate)
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT04145375 -
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04729114 -
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02266745 -
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
|
Phase 2 | |
| Recruiting |
NCT05413850 -
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05340374 -
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04822961 -
Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT03395197 -
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
|
Phase 3 | |
| Recruiting |
NCT05547061 -
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03851640 -
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).
|
Phase 3 |